Background: Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (...
R. Pinninti, K. Subramaniyan, R. Iyer et al.· Journal of Clinical Medicine· 0 citations
An evidence-informed, consensus-based tool to support recurrence risk stratification and treatment decision-making in patients with HR+/HER2– EBC, incorporating multidisciplinary perspectives and evolving evidence from guidelines and trials is developed.
K. Mallavarapu, R. Reddy B, Somashekhar Sp et al.· Breast Cancer· 0 citations
Integration of molecular classification modified adjuvant treatment in approximately one fifth of patients, supporting the feasibility and clinical utility of molecularly integrated MDT decision making in early-stage endometrial cancer even in resource-constrained settings.
R. Pinninti, H. Abbaraju, Krishna Mohan Mallavarapu et al.· JCO Global Oncology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.